| Abstract P258 – Table 1. Demographic and clinical characteristics of patients with mild COVID‐19, according to anti‐SARS‐CoV‐2 antiviral treatment. | |||||
|---|---|---|---|---|---|
| Characteristics | Study population | MNP | PAX | RDV | p‐value |
| N = 178 | N = 78 | N = 44 | N = 56 | ||
| (43.8%) | (24.7%) | (31.5%) | |||
| Age [years], median (IQR) | 74 (58 to 82) | 78 (66 to 84) | 59 (49 to 78) | 73 (63 to 83) | <0.001 |
| Male sex, n (%) | 100 (56.2%) | 52 (67.5%) | 20 (45.5%) | 28 (50%) | 0.031 |
| COVID‐19 vaccination, n (%) | 0.661 | ||||
| No | 32 (18%) | 14 (17.9%) | 6 (18.8%) | 12 (37.5%) | |
| Yes | 144 (80.9%) | 64 (82.1%) | 36 (25%) | 44 (30.6%) | |
| (complete schedule, <120 days)a | |||||
| Unknown | 2 (1.1%) | 0 | 2 (4.5%) | 0 | |
| Risk factor, n (%) | |||||
| Age >65 years | 105 (59%) | 55 (70.5%) | 12 (27.3%) | 38 (67.9%) | <0.001 |
| BMI >30 | 20 (11.2%) | 7 (9%) | 6 (13.6%) | 7 (12.5%) | 0.689 |
| Cardiovascular disease | 75 (42.1%) | 42 (53.8%) | 8 (18.2%) | 25 (44.6%) | <0.001 |
| COPD or other respiratory disease | 38 (21.3%) | 15 (19.2%) | 10 (22.7%) | 13 (23.2%) | 0.829 |
| Neurological disease | 11 (6.2%) | 4 (5.1%) | 2 (4.5%) | 5 (8.9%) | 0.582 |
| Diabetes mellitus | 34 (19.1%) | 14 (17.9%) | 5 (11.4%) | 15 (26.8%) | 0.141 |
| Chronic kidney failure | 10 (5.6%) | 7 (9%) | 0 | 3 (5.4%) | 0.117 |
| Cancer | 12 (6.7%) | 5 (6.4%) | 3 (6.8%) | 4 (7.1%) | 0.986 |
| Immunodeficiency | 27 (15.2%) | 8 (10.3%) | 12 (27.3%) | 7 (12.5%) | 0.034 |
| Treatments for COVID‐19, n (%) | |||||
| Heparin | 16 (9%) | 3 (4%) | 2 (5.6%) | 11 (20.8%) | 0.004 |
| Corticosteroid therapy | 4 (2.2%) | 1 (1.3%) | 1 (2.8%) | 2 (3.8%) | 0.671 |
| Symptoms, n (%) | <0.001 | ||||
| None | 14 (7.9%) | 2 (2.6%) | 1 (2.3%) | 11 (19.6%) | |
| Yes | 164 (92.1%) | 76 (97.4%) | 43 (97.7%) | 45 (80.4%) | |
| Type of symptoms | |||||
| Fever | 76 (42.7%) | 36 (46.2%) | 21 (47.7%) | 19 (33.9%) | 0.273 |
| Cough | 85 (47.8%) | 38 (48.7%) | 22 (50%) | 25 (44.6%) | 0.846 |
| Sore throat | 34 (19.1%) | 15 (19.2%) | 14 (31.8%) | 5 (8.9%) | 0.015 |
| Headache | 15 (8.4%) | 4 (5.1%) | 6 (13.6%) | 5 (8.9%) | 0.264 |
| Joint/muscle pain | 14 (7.9%) | 6 (7.7%) | 5 (11.4%) | 3 (5.4%) | 0.540 |
| Gastrointestinal disorders | 7 (3.9%) | 3 (3.8%) | 2 (4.5%) | 2 (3.6%) | 0.968 |
| Dyspnoea | 16 (9%) | 3 (3.8%) | 3 (6.8%) | 10 (17.9%) | 0.017 |
| Fatigue | 32 (18%) | 16 (20.5%) | 10 (22.7%) | 6 (10.7%) | 0.221 |
| Cold | 13 (7,3%) | 10 (12.8%) | 10 (22.7%) | 3 (5.4%) | 0.037 |
| Oxygen saturation >94%, median (IQR) | 155 (87.1%) | 97 (96 to 98) | 97 (96 to 98) | 96 (95 to 98) | 0.180 |
| Setting, n (%) | <0.001 | ||||
| Outpatient service | 148 (83.1%) | 75 (96.2%) | 41 (93.2%) | 32 (57.1%) | |
| Hospitalisation for diseases other than COVID‐19 | 30 (16.9%) | 3 (3.8%) | 3 (6.8%) | 24 (42.9%) | |
| Days from symptom onset to antiviral treatment, median (IQR) | 3 (2 to 4) | 3 (2 to 4) | 3 (2 to 4) | 2 (1 to 4) | 0.958 |
| Days from symptom onset to virological clearance, median (IQR) | 13 (10 to 18) | 15 (11 to 18) | 11 (9 to 15) | 13 (9 to 19) | 0.015 |
| Outcome, n (%) | N = 158 | N = 73 | N = 32 | N = 53 | 0.850 |
| Recovery | 150 (94.9%) | 70 (95.9%) | 31 (96.9%) | 49 (92.5%) | |
| Hospitalisation | 2 (1.3%) | 1 (1.4%) | 0 | 1 (1.9%) | |
| Death | 6 (3.8%) | 2 (2.7%) | 1 (3.1%) | 3 (5.7%) | |
| Adverse events, n (%) | N = 148 | N = 67 | N = 30 | N = 51 | 0.321 |
| No | 144 (97.3%) | 66 (98.5%) | 28 (93.3%) | 50 (98%) | |
| Yes | 4 (2.7%) | 1 (1.5%) | 2 (6.7%) | 1 (2%) | |
| Virological clearance at day 7 from symptoms onset, n (%) | N = 133 | N = 60 | N = 26 | N = 47 | 0.053 |
| No | 82 (61.7%) | 42 (70%) | 11 (42.3%) | 29 (61.7%) | |
| Yes | 51 (38.3%) | 18 (30%) | 15 (57.7%) | 18 (38.3%) | |
| Calendar period, n (%) | <0.001 | ||||
| Jan to Feb 2022 | 62 (34.8%) | 35 (44.9%) | 3 (4.8%) | 24 (42.9%) | |
| Mar to Apr 2022 | 58 (32.6%) | 33 (56.9%) | 17 (38.6%) | 8 (14.3%) | |
| May to Jun 2022 | 58 (32.6%) | 10 12.8%) | 24 (54.5%) | 24 (42.9%) | |
aVaccination: no dose: 15, 8.4% ‐ yes, only 1 dose: 4, 2.2% ‐ complete cycle: 20, 11.2% ‐ first booster dose: 136, 76.4% ‐ second booster dose: 1, 0.6%.
Kruskal Wallis and Chi‐squared test for comparison among the three groups, as appropriate.